维普中文期刊产品整合服务
6篇 您的检索式:作者名="Vuslat"
    题名 作者 年代 出处 被引量
1Comparison of long-term results of trabeculectomy to treat pseudoexfoliative glaucoma and primary open angle glaucoma显示文摘AIM: To compare the long term outcome of trabeculectomy in patients with pseudoexfoliative glaucoma(PEG) and primary open angle glaucoma(POAG) in terms of surgical success. METHODS: The success of the trabeculectomy was evaluated by three criteria. Criterion A: intraocular pressure(IOP) ≤21 mm Hg and decrease in IOP ≥20%; Criterion B: IOP ≤18 mm Hg and decrease in IOP ≥30%; Criterion C: IOP ≤15 mm Hg and decrease in IOP ≥50%. Patients that met these criteria without medical treatment were considered to be completely successful, while those that met these criteria with medical treatment were considered partially successful. Significance levels of differences between the POAG and PEG groups in the Kaplan-Meier survival curves were calculated with the log-rank test. RESULTS: Sixty-four eyes from 64 patients with PEG and 51 eyes from 51 patients with POAG were evaluated. No significant differences were detected between the PEG and POAG groups according to full or partial success relative to each of the three criteria(A: P=0.73, 0.32; B: P=0.73, 0.31; C:P=0.90, 0.27). CONCLUSION: There is no difference in the long-term success of trabeculectomy between PEG and POAG patients whose clinical characteristics are otherwise the same.Vuslat Pelitli Gürlü Hande Gürlü Altan Ozal Omer Benian Levent Alimgil 2018International Journal of Ophthalmology(English edition)2018,11,1:3
2Comparison of topical nepafenac 0.1% with intravitreal dexamethasone implant for the treatment of Irvine-Gass syndrome显示文摘AIM: To compare safety and efficacy of intravitreal dexamethasone(IVD) implant with topical nepafenac(TN) 0.1% in previously untreated Irvine-Gass syndrome(IGS) in clinical practice. METHODS: This was a retrospective study of 62 eyes with IGS after phacoemulsification with posterior chamber intraocular lens(IOL) implantation. None of the patients used treatment before IVD or TN. Best-corrected visual acuity(BCVA) with Early Treatment Diabetic Retinopathy Study chart(ETDRS), slit-lamp, intraocular pressure(IOP) measurement, fundus examination, spectral-domain optical coherence tomography(OCT) and fundus florescein angiography were performed to all subjects at baseline, 1, 3 and 6 mo. RESULTS: The mean BCVA of the IVD group was 49.3±6.8, and the mean BCVA of the TN group was 32.9±7.3 ETDRS letters in post-treatment month 6. The mean central macular thickness(CRT) of IVD group was 266.6±53.5 μm and the mean CRT of TN group was 364.9±56.3 μm in posttreatment month 6. Baseline BCVA has correlation with final BCVA in TN group however there was no correlation between baseline BCVA and final BCVA in IVD group. CONCLUSION: IVD is found to be better than TN in controlling pseudophakic macular edema and improving visual acuity. IVD group also has significantly lower CRT however IOP is not significantly different between two groups in post-treatment month 6.Hande Guclu Vuslat Pelitli Gurlu 2019International Journal of Ophthalmology(English edition)2019,12,2:2
3Paraneoplastic syndrome of non-small cell lung carcinoma:A case with pancytopenia, leukocy- toclastic vasculitis,and hypertrophic osteoarthropathy显示文摘Rusen CA Vuslat YC Hakan K 2007Lung Can- cer2007,56,3:1
4Ahmet Ucaner Timing of surgi- cal treatment for type III supracondylar humerus fractures in pediatric patients显示文摘Vuslat U Ozdamar O Murat G 2009J Child Orthop2009,3,11:1
5Prepubertal anti-Musk positive myasthenia gravis with long remission显示文摘Ozlem Gungor-Tuncer Elif Kocasoy Orhan Vuslat Yilmaz 2014Neuromuscular Disorders2014,24,1:1
6Recurrent solitary fibrous tumor of the pleura: significant response to radiotherapy显示文摘Mert Saynak Gulden Bayir-Angin Zafer Kocak Fulya Oz-Puyan Murat Hayar Rusen Cosar-Alas Altemur Karamustafaoglu Vuslat Yurut-Caloglu Murat Caloglu Yener Yoruk 2010Medical Oncology2010,,1:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费